
AstraZeneca’s investment will “span the value chain” of drug research and development and comes amid a prolonged surge in dealmaking activity involving large pharmaceutical companies and their counterparts in China.

AstraZeneca’s investment will “span the value chain” of drug research and development and comes amid a prolonged surge in dealmaking activity involving large pharmaceutical companies and their counterparts in China.